Found: 101
Select item for more details and to access through your institution.
Bax membrane insertion during Fas(CD95)-induced apoptosis precedes cytochrome c release and is inhibited by Bcl-2.
- Published in:
- Oncogene, 1999, v. 18, n. 44, p. 5991, doi. 10.1038/sj.onc.1203001
- By:
- Publication type:
- Article
Stability of gene expression and epigenetic profiles highlights the utility of patient-derived paediatric acute lymphoblastic leukaemia xenografts for investigating molecular mechanisms of drug resistance.
- Published in:
- BMC Genomics, 2014, v. 15, n. 1, p. 1, doi. 10.1186/1471-2164-15-416
- By:
- Publication type:
- Article
The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia.
- Published in:
- Science Translational Medicine, 2016, v. 8, n. 339, p. 1, doi. 10.1126/scitranslmed.aad3099
- By:
- Publication type:
- Article
Reduced Immunogenicity of First-Trimester Human Fetal Pancreas.
- Published in:
- Diabetes, 2008, v. 57, n. 3, p. 627, doi. 10.2337/db07-0720a
- By:
- Publication type:
- Article
Validation of a mouse xenograft model system for gene expression analysis of human acute lymphoblastic leukaemia.
- Published in:
- BMC Genomics, 2010, v. 11, p. 256, doi. 10.1186/1471-2164-11-256
- By:
- Publication type:
- Article
Differential patterns of anti-tumour drug responses and mechanisms of resistance in a series of independently-derived VP-16-resistant human tumour cell lines.
- Published in:
- International Journal of Cancer, 1988, v. 42, n. 3, p. 373, doi. 10.1002/ijc.2910420312
- By:
- Publication type:
- Article
Exploiting the reactive oxygen species imbalance in high-risk paediatric acute lymphoblastic leukaemia through auranofin.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Examining treatment responses of diagnostic marrow in murine xenografts to predict relapse in children with acute lymphoblastic leukaemia.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Reversal of glucocorticoid resistance in paediatric acute lymphoblastic leukaemia is dependent on restoring BIM expression.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Methotrexate and aminopterin exhibit similar in vitro and in vivo preclinical activity against acute lymphoblastic leukaemia and lymphoma.
- Published in:
- British Journal of Haematology, 2009, v. 145, n. 3, p. 389, doi. 10.1111/j.1365-2141.2009.07631.x
- By:
- Publication type:
- Article
A xenograft model of infant leukaemia reveals a complex MLL translocation.
- Published in:
- 2008
- By:
- Publication type:
- Letter
Anesthetic concerns for pediatric patients in the era of COVID‐19.
- Published in:
- Pediatric Anesthesia, 2020, v. 30, n. 7, p. 737, doi. 10.1111/pan.13924
- By:
- Publication type:
- Article
Author Correction: Small molecule inhibition of Dynamin-dependent endocytosis targets multiple niche signals and impairs leukemia stem cells.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Small molecule inhibition of Dynamin-dependent endocytosis targets multiple niche signals and impairs leukemia stem cells.
- Published in:
- Nature Communications, 2020, v. 11, n. 1, p. 1, doi. 10.1038/s41467-020-20091-6
- By:
- Publication type:
- Article
Disparate In Vivo Efficacy of FTY720 in Xenograft Models of Philadelphia Positive and Negative B-lineage Acute Lymphoblastic Leukemia.
- Published in:
- PLoS ONE, 2012, v. 7, n. 5, p. 1, doi. 10.1371/journal.pone.0036429
- By:
- Publication type:
- Article
Pharmacokinetic Modeling of an Induction Regimen for In Vivo Combined Testing of Novel Drugs against Pediatric Acute Lymphoblastic Leukemia Xenografts.
- Published in:
- PLoS ONE, 2012, v. 7, n. 3, p. 1, doi. 10.1371/journal.pone.0033894
- By:
- Publication type:
- Article
Pronounced Hypoxia in Models of Murine and Human Leukemia: High Efficacy of Hypoxia-Activated Prodrug PR-104.
- Published in:
- PLoS ONE, 2011, v. 6, n. 8, p. 1, doi. 10.1371/journal.pone.0023108
- By:
- Publication type:
- Article
In vivo activity of the dual SYK/FLT3 inhibitor TAK‐659 against pediatric acute lymphoblastic leukemia xenografts.
- Published in:
- Pediatric Blood & Cancer, 2023, v. 70, n. 9, p. 1, doi. 10.1002/pbc.30503
- By:
- Publication type:
- Article
In vivo activity of the dual PI3Kδ and PI3Kγ inhibitor duvelisib against pediatric acute lymphoblastic leukemia xenografts.
- Published in:
- Pediatric Blood & Cancer, 2023, v. 70, n. 8, p. 1, doi. 10.1002/pbc.30398
- By:
- Publication type:
- Article
Optimization of a clofarabine-based drug combination regimen for the preclinical evaluation of pediatric acute lymphoblastic leukemia.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Preclinical activity of the antibody-drug conjugate denintuzumab mafodotin (SGN-CD19A) against pediatric acute lymphoblastic leukemia xenografts.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program.
- Published in:
- Pediatric Blood & Cancer, 2015, v. 62, n. 6, p. 1106, doi. 10.1002/pbc.25329
- By:
- Publication type:
- Article
Efficacy of CPX-351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program.
- Published in:
- Pediatric Blood & Cancer, 2015, v. 62, n. 1, p. 65, doi. 10.1002/pbc.25133
- By:
- Publication type:
- Article
Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.
- Published in:
- Pediatric Blood & Cancer, 2015, v. 62, n. 1, p. 91, doi. 10.1002/pbc.25201
- By:
- Publication type:
- Article
Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program.
- Published in:
- Pediatric Blood & Cancer, 2014, v. 61, n. 8, p. 1493, doi. 10.1002/pbc.25026
- By:
- Publication type:
- Article
Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program.
- Published in:
- Pediatric Blood & Cancer, 2014, v. 61, n. 8, p. 1486, doi. 10.1002/pbc.24989
- By:
- Publication type:
- Article
Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program.
- Published in:
- Pediatric Blood & Cancer, 2014, v. 61, n. 2, p. 245, doi. 10.1002/pbc.24724
- By:
- Publication type:
- Article
Initial testing (stage 1) of the polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.
- Published in:
- Pediatric Blood & Cancer, 2014, v. 61, n. 1, p. 158, doi. 10.1002/pbc.24616
- By:
- Publication type:
- Article
Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program.
- Published in:
- Pediatric Blood & Cancer, 2013, v. 60, n. 8, p. 1325, doi. 10.1002/pbc.24517
- By:
- Publication type:
- Article
Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the pediatric preclinical testing program.
- Published in:
- Pediatric Blood & Cancer, 2013, v. 60, n. 7, p. E42, doi. 10.1002/pbc.24451
- By:
- Publication type:
- Article
Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program.
- Published in:
- Pediatric Blood & Cancer, 2013, v. 60, n. 5, p. 783, doi. 10.1002/pbc.24368
- By:
- Publication type:
- Article
Initial testing (stage 1) of the phosphatidylinositol 3′ kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program.
- Published in:
- Pediatric Blood & Cancer, 2013, v. 60, n. 5, p. 791, doi. 10.1002/pbc.24301
- By:
- Publication type:
- Article
Initial testing of the MDM2 inhibitor RG7112 by the pediatric preclinical testing program.
- Published in:
- Pediatric Blood & Cancer, 2013, v. 60, n. 4, p. 633, doi. 10.1002/pbc.24235
- By:
- Publication type:
- Article
Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program.
- Published in:
- Pediatric Blood & Cancer, 2012, v. 59, n. 7, p. 1266, doi. 10.1002/pbc.24073
- By:
- Publication type:
- Article
Erratum: Malcolm A. Smith, John M. Maris, Richard Gorlick, E. Anders Kolb, Richard Lock, Hernan Carol, Stephen T. Keir, C. Patrick Reynolds, Min H. Kang, Christopher L. Morton, Jianrong Wu, Peter G. Smith, Jie Yu and Peter J. Houghton. Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2012 August; 59(2):246-253
- Published in:
- Pediatric Blood & Cancer, 2012, v. 59, n. 4, p. 772, doi. 10.1002/pbc.24291
- By:
- Publication type:
- Article
Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program.
- Published in:
- Pediatric Blood & Cancer, 2012, v. 59, n. 4, p. 749, doi. 10.1002/pbc.23364
- By:
- Publication type:
- Article
Testing of the Akt/PKB inhibitor MK-2206 by the pediatric preclinical testing program.
- Published in:
- Pediatric Blood & Cancer, 2012, v. 59, n. 3, p. 518, doi. 10.1002/pbc.23412
- By:
- Publication type:
- Article
Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program.
- Published in:
- Pediatric Blood & Cancer, 2012, v. 59, n. 2, p. 246, doi. 10.1002/pbc.23357
- By:
- Publication type:
- Article
Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program.
- Published in:
- Pediatric Blood & Cancer, 2012, v. 59, n. 2, p. 329, doi. 10.1002/pbc.23319
- By:
- Publication type:
- Article
Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program.
- Published in:
- Pediatric Blood & Cancer, 2012, v. 59, n. 1, p. 185, doi. 10.1002/pbc.23154
- By:
- Publication type:
- Article
Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program.
- Published in:
- Pediatric Blood & Cancer, 2012, v. 58, n. 6, p. 916, doi. 10.1002/pbc.23176
- By:
- Publication type:
- Article
Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling.
- Published in:
- Pediatric Blood & Cancer, 2012, v. 58, n. 5, p. 815, doi. 10.1002/pbc.23290
- By:
- Publication type:
- Article
Initial testing (stage 1) of LCL161, a SMAC mimetic, by the pediatric preclinical testing program.
- Published in:
- Pediatric Blood & Cancer, 2012, v. 58, n. 4, p. 636, doi. 10.1002/pbc.23167
- By:
- Publication type:
- Article